(+)-Sesamin, a sesame lignan, is a potent inhibitor of gut bacterial tryptophan indole-lyase that is a key enzyme in chronic kidney disease pathogenesis.
(+)-Sesamin, a sesame lignan, is a potent inhibitor of gut bacterial tryptophan indole-lyase that is a key enzyme in chronic kidney disease pathogenesis.
复制标题
( )-Sesamin 是一种芝麻木脂素,是肠道细菌色氨酸吲哚裂解酶的有效抑制剂,而色氨酸吲哚裂解酶是慢性肾病发病机制中的关键酶。
DOI:
10.1016/j.bbrc.2021.12.088
复制
发表时间:
2022
影响因子:
3.1
通讯作者:
Nakayama T.
中科院分区:
文献类型:
--
作者:
16.Oikawa D;Yamashita S;Takahashi S;Waki T;Kikuchi K;Abe T;Katayama T;Nakayama T.
The progression of chronic kidney disease (CKD) increases the risks of cardiovascular morbidity and end-stage kidney disease. Indoxyl sulfate (IS), which is derived from dietaryl-tryptophan by the action of bacteriall-tryptophan indole-lyase (TIL) in the gut, serves as a uremic toxin that exacerbates CKD-related kidney disorder. A mouse model previously showed that inhibition of TIL by 2-aza-l-tyrosine effectively reduced the plasma IS level, causing the recovery of renal damage. In this study, we found that (+)-sesamin and related lignans, which occur abundantly in sesame seeds, inhibit intestinal bacteria TILs. Kinetic studies revealed that (+)-sesamin and sesamol competitively inhibitedEscherichia coliTIL (EcTIL) withKivalues of 7 μM and 14 μM, respectively. TheseKivalues were smaller than that of 2-aza-l-tyrosine (143 μM). Molecular docking simulation of (+)-sesamin- (or sesamol-)binding to EcTIL predicted that these inhibitors potentially bind near the active site of EcTIL, where the cofactor pyridoxal 5′-phosphate is bound, consistent with the kinetic results. (+)-Sesamin is a phytochemical with a long history of consumption and is generally regarded as safe. Hence, dietary supplementation of (+)-sesamin encapsulated in enteric capsules could be a promising mechanism-based strategy to prevent CKD progression. Moreover, the present findings would provide a new structural basis for designing more potent TIL inhibitors for the development of mechanism-based therapeutic drugs to treat CKD.
登录
查看更多内容
DOI:
--
发表时间:
2019
期刊:
影响因子:
--
作者:
Nakagama Yu;Takeda Norihiko;Ogawa Seishi;Takeda Hiroyuki;Furutani Yoshiyuki;Nakanishi Toshio;Sato Tatsuyuki;Hirata Yoichiro;Oka Akira;Inuzuka Ryo;菊地晃一
通讯作者:
菊地晃一
影响因子:
5.1
作者:
Phillips,RobertS;Demidkina,TatyanaV;Faleev,NicolaiG
通讯作者:
Faleev,NicolaiG
影响因子:
2.9
作者:
Watkins Eb;Phillips Rs
通讯作者:
Phillips Rs
影响因子:
2.7
作者:
T. Koyanagi;T. Katayama;Ai Hirao;Hideyuki Suzuki;H. Kumagai
通讯作者:
H. Kumagai
影响因子:
3.9
作者:
Do, Quang T.;Nguyen, Giang T.;Phillips, Robert S.
通讯作者:
Phillips, Robert S.